brompheniramine (redirected from Nasahist B)

brompheniramine /brom·phen·ir·amine/ (brōm″fen-ir´ah-mēn) an antihistamine with anticholinergic and sedative effects, used as the maleate salt.

---

brompheniramine [brōm″fen-ir´ah-mēn]

an antihistamine with sedative and anticholinergic effects; used as the maleate salt in the treatment of nasal, eye, and skin manifestations of allergic reactions, including allergic rhinitis, conjunctivitis, and itching, administered orally or by intramuscular, intravenous, or subcutaneous injection. The maleate salt is also an ingredient in some cold and cough preparations, administered orally.

---

brompheniramine

a histamine H₁-receptor antagonist used in the treatment of hypersensitivity reactions and allergic skin diseases.

---

brompheniramine

Bromfenac, Brove X, Dimetane, Dimetapp Allergy, Nasahist B, ND-Stat

Pharmacologic class: Histamine antagonist

Therapeutic class: Antihistamine

Pregnancy risk category C

Action

Antagonizes effects of histamine at histamine₁-receptor sites, but doesn't bind to or inactivate histamine. Also shows anticholinergic, antipruritic, and sedative activity.

Availability

Capsules (liquigels): 4 mg

Elixir: 2 mg/5 ml

Suspension: 12 mg/5 ml

Tablets: 4 mg, 8 mg, 12 mg

Tablets (extended-release): 8 mg, 12 mg

⊘Indications and dosages

➣ Symptomatic relief of allergic symptoms caused by histamine release; severe allergic or hypersensitivity reactions

Adults and children ages 12 and older: 4 to 8 mg P.O. three to four times daily, or 8 to 12 mg extended-release tablets P.O. two or three times daily. Maximum dosage is 36 mg/day.

Children ages 6 to 12: 2 mg P.O. q 4 to 6 hours as needed, not to exceed 12 mg/day

Children ages 2 to 6: 1 mg P.O. q 4 to 6 hours p.r.n., not to exceed 6 mg/day

Contraindications

• Hypersensitivity to drug
• Coronary artery disease
• Urinary retention
• Pyloroduodenal obstruction
• Peptic ulcer
• MAO inhibitor use within past 14 days
• Breastfeeding

Precautions

Use cautiously in:
• angle-closure glaucoma, hepatic disease, hyperthyroidism, hypertension, bronchial asthma
• elderly patients
• pregnant patients.

Administration

• Give with food if GI upset occurs.
• Don't break or crush extended-release tablets.
• Shake oral suspension well before measuring dose.
☞ Check elixir and suspension doses carefully, because the mg/ml varies widely between the two liquids.

Route	Onset	Peak	Duration
P.O.	15-60 min	2-5 hr	3-24 hr

Adverse reactions

CNS: drowsiness, sedation, dizziness, excitation, irritability, syncope, tremor

CV: hypertension, hypotension, palpitations, tachycardia, extrasystole, arrhythmias, bradycardia

EENT: blurred vision, nasal congestion or dryness, dry or sore throat

GI: nausea, vomiting, constipation, dry mouth

GU: urinary retention or hesitancy, dysuria, early menses, decreased libido, impotence

Hematologic: hemolytic anemia, hypoplastic anemia, thrombocytopenia, agranulocytosis, leukopenia, pancytopenia

Respiratory: thickened bronchial secretions, chest tightness, wheezing

Skin: urticaria, rash

Other: increased or decreased appetite, weight gain

Interactions

Drug-drug. CNS depressants (including opioids and sedative-hypnotics): additive CNS depression

MAO inhibitors: intensified, prolonged anticholinergic effects

Drug-diagnostic tests. Allergy tests: false results

Granulocytes, platelets: decreased counts

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

• Monitor respiratory status.
• Stay alert for urinary retention, urinary frequency, and painful or difficult urination. Discontinue drug if these problems occur.
• With long-term use, monitor CBC.
• Monitor elderly patient for dizziness, sedation, and hypotension.
• If patient takes over-the-counter antihistamines, monitor him closely to avoid potential overdose.

Patient teaching

• Advise patient to take drug with meals if GI upset occurs.
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Caution patient to avoid alcohol while taking drug.
• Urge patient to tell all prescribers which drugs and over-the-counter preparations he's taking.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.